The immunology of atherothrombosis in the antiphospholipid syndrome: Antigen presentation and lipid intracellular accumulation

Autoimmunity Reviews

Volumn 8, Issue 6, 2009, Pages 500-505

  Matsuura, Eiji ^a   Kobayashi, Kazuko ^a   Matsunami, Yukana ^a   Lopez, Luis R ^b  

^a OKAYAMA UNIVERSITY   (Japan)

^b Division of Medicine   (United States)

Author keywords

2 glycoprotein I ( 2GPI); Antigen presentation; Antiphospholipid syndrome (APS); Atherothrombosis; Oxidized LDL (oxLDL)

Indexed keywords

BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY; FC RECEPTOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID ANTIBODY;

ANTIGEN PRESENTATION; ANTIPHOSPHOLIPID SYNDROME; ATHEROTHROMBOSIS; AUTOIMMUNITY; HUMAN; HYPERCOAGULABILITY; LIPID STORAGE; MACROPHAGE; PROTEIN TARGETING; REVIEW; T LYMPHOCYTE; THROMBOSIS; VASCULITIS;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIGEN PRESENTATION; ANTIGEN-ANTIBODY COMPLEX; ANTIPHOSPHOLIPID SYNDROME; ARTERIES; AUTOANTIGENS; BETA 2-GLYCOPROTEIN I; CD4-POSITIVE T-LYMPHOCYTES; HUMANS; LIPID METABOLISM; LIPOPROTEINS, LDL; MACROPHAGES; RECEPTORS, IGG; THROMBOPHILIA; THROMBOSIS;

EID: 67349109452     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2008.12.018     Document Type: Review

References (40)

1. Matsuura E., Igarashi Y., Yasuda T., Triplett D.A., and Koike T. Anticardiolipin antibodies recognize β2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 179 (1994) 457-462
2. McNeil H.P., Simpson R.J., Chesterman C.N., and Krilis S.A. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 87 (1990) 4120-4124
3. Vaarala O. Antiphospholipid antibodies in myocardial infarction. Lupus 7 (1998) S132-134
4. Brey R.L., Abbott R.D., Curb J.D., Sharp D.S., Ross G.W., Stallworth C.L., et al. β2-glycoprotein I dependent anticardiolipin antibodies and the risk of ischemic stroke and myocardial infarction. Stroke 32 (2001) 1701-1706
5. Lopez L.R., Dier K.J., Lopez D., Merrill J.T., and Fink C.A. Anti-β2-glycoprotein I and antiphosphatidylserine antibodies are predictors of arterial thrombosis in patients with antiphospholipid syndrome. Am J Clin Pathol 121 (2004) 142-149
6. Ylä-Herttuala S., Palinski W., Rosenfeld M.E., Parthasarathy S., Carew T.E., Butler S., et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 84 (1989) 1086-1095
7. Lehtimäki T., Lehtinen S., Solakivi T., Nikkilä M., Jaakkola O., Jokela H., et al. Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease. Arterioscler Thromb Vasc Biol 19 (1999) 23-27
8. Yasunobu Y., Hayashi K., Shingu T., Yamagata T., Kajiyama G., and Kambe M. Coronary atherosclerosis and oxidative stress as reflected by autoantibodies against oxidized low-density lipoprotein and oxysterols. Atherosclerosis 155 (2001) 445-453
9. Hasunuma Y., Matsuura E., Makita Z., Katahira T., Nishi S., and Koike T. Involvement of β2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 107 (1997) 569-573
10. Kobayashi K., Matsuura E., Liu Q., Furukawa J., Kaihara K., Inagaki J., et al. A specific ligand for β2-glycoprotein I mediates autoantibody-dependent uptake of oxidized low density lipoprotein by macrophages. J Lipid Res 42 (2001) 697-709
11. Liu Q., Kobayashi K., Furukawa J., Inagaki J., Sakairi N., Iwado A., et al. Omega-carboxyl variants of 7-ketocholesteryl esters are ligands for β2-glycoprotein I and mediate antibody-dependent uptake of oxidized LDL by macrophages. J Lipid Res 43 (2002) 1486-1495
12. Kobayashi K., Kishi M., Atsumi T., Bertolaccini M.L., Makino H., Sakairi N., et al. Circulating oxidized LDL forms complexes with β2-glycoprotein I: implication as an atherogenic autoantigen. J Lipid Res 44 (2003) 716-726
13. Matsuura E., Kobayashi K., Tabuchi M., and Lopez L.R. Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis. Prog Lipid Res 45 (2006) 466-486
14. Tabuchi M., Inoue K., Usui-Kataoka H., Kobayashi K., Teramoto M., Takasugi K., et al. The association of C-reactive protein with an oxidative metabolite of LDL and its implication in atherosclerosis. J Lipid Res 48 (2007) 768-781
15. Kuwana M., Matsuura E., Kobayashi K., Okazaki Y., Kaburaki J., Ikeda Y., et al. Binding of β2-glycoprotein I to anionic phospholipids facilitates processing and presentation of a cryptic epitope that activates pathogenic autoreactive T cells. Blood 105 (2005) 1552-1557
16. Yamaguchi Y., Seta N., Kaburaki J., Kobayashi K., Matsuura E., and Kuwana M. Excessive exposure to anionic surfaces maintains autoantibody response to β2-glycoprotein I in patients with antiphospholipid syndrome. Blood 110 (2007) 4312-4318
17. Kajiwara T., Yasuda T., and Matsuura E. Intracellular trafficking of β2-glycoprotein I complexes with lipid vesicles in macrophages: implications on the development of antiphospholipid syndrome. J Autoimmun 29 (2007) 164-173
18. Kobayashi K., Tada K., Itabe H., Ueno T., Liu P.H., Tsutsumi A., et al. Distinguished effects of antiphospholipid antibodies and anti-oxidized LDL antibodies on oxidized LDL uptake by macrophages. Lupus 16 (2007) 929-938
19. Harris E.N., Chan J.K., Asherson R.A., Aber V.R., Gharavi A.E., and Hughes G.R. Thrombosis, recurrent fetal loss, and thrombocytopenia. Predictive value of the anticardiolipin antibody test. Arch Intern Med 146 (1986) 2153-2156
20. Ginsburg K.S., Liang M.H., Newcomer L., Goldhaber S.Z., Schur P.H., Hennekens C.H., et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 117 (1992) 997-1002
21. Hughes G.R., Harris N.N., and Gharavi A.E. The anticardiolipin syndrome. J Rheumatol 13 (1986) 486-489
22. Hunt J.E., McNeil H.P., Morgan G.J., Crameri R.M., and Krilis S.A. A phospholipid-β2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection. Lupus 1 (1992) 75-81
23. Matsuura E., Igarashi Y., Fujimoto M., Ichikawa K., and Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 336 (1990) 177-178
24. Matsuura E., Igarashi Y., Fujimoto M., Ichikawa K., Suzuki T., Sumida T., et al. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol 148 (1992) 3885-3891
25. Herrmann M., Voll R.E., Zoller O.M., Hagenhofer M., Ponner B.B., and Kalden J.R. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 41 (1998) 1241-1250
26. Arai T., Yoshida K., Kaburaki J., Inoko H., Ikeda Y., Kawakami Y., et al. Autoreactive CD4(+) T-cell clones to β2-glycoprotein I in patients with antiphospholipid syndrome: preferential recognition of the major phospholipid-binding site. Blood 98 (2001) 1889-1896
27. Tsutsumi A., Matsuura E., Ichikawa K., Fujisaku A., Mukai M., Kobayashi S., et al. Antibodies to β2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum 39 (1996) 1466-1474
28. George J., Harats D., Gilburd B., Afek A., Levy Y., Schneiderman J., et al. Immunolocalization of β2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation 99 (1999) 2227-2230
29. Shoenfeld Y., Wu R., Dearing L.D., and Matsuura E. Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective?. Circulation 110 (2004) 2552-2558
30. Shoenfeld Y., Gerli R., Doria A., Matsuura E., Cerinic M.M., Ronda N., et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112 (2005) 3337-3347
31. Cervera R., Piette J.C., Font J., Khamashta M.A., Shoenfeld Y., Camps M.T., et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46 (2002) 1019-1027
32. Fong L.G., Parthasarathy S., Witztum J.L., and Steinberg D. Nonenzymatic oxidative cleavage of peptide bonds in apoprotein B-100. J Lipid Res 28 (1987) 1466-1477
33. Esterbauer H., Jurgens G., Quehenberger O., and Koller E. Autoxidation of human low density lipoprotein: loss of polyunsaturated fatty acids and vitamin E and generation of aldehydes. J Lipid Res 28 (1987) 495-509
34. Morgan P.E., Sturgess A.D., and Davies M. Increased levels of serum protein oxidation and correlation with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 52 (2005) 2069-2079
35. Frostegård J., Svenungsson E., Wu R., Gunnarsson I., Lundberg I.E., Klareskog L., et al. Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum 52 (2005) 192-200
36. Lopez D., Kobayashi K., Merrill J.T., Matsuura E., and Lopez L.R. IgG Autoantibodies against β2-glycoprotein I complexed with a lipid ligand derived from oxidized low-density lipoprotein are associated with arterial thrombosis in antiphospholipid syndrome. Clin Dev Immunol 10 (2003) 203-211
37. Dunoyer-Geindre S., Kruithof E.K., Galve-de Rochemonteix B., Rosnoblet C., Gruenberg J., Reber G., et al. Localization of β2-glycoprotein 1 in late endosomes of human endothelial cells. Thromb Haemost 85 (2001) 903-907
38. Galve-de Rochemonteix B., Kobayashi T., Rosnoblet C., Lindsay M., Parton R.G., Reber G., et al. Interaction of anti-phospholipid antibodies with late endosomes of human endothelial cells. Arterioscler Thromb Vasc Biol 20 (2000) 563-574
39. Matsuura E., Kobayashi K., and Lopez L.R. Preventing autoimmune and infection triggered atherosclerosis for an enduring healthful lifestyle. Autoimmun Rev 7 (2008) 214-222
40. Matsuura E., Hughes G.R., and Khamashta M.A. Oxidation of LDL and its clinical implication. Autoimmun Rev 7 (2008) 558-566